Ciprofloxacin 0.3% ophthalmic solution is indicated for the treatment of corneal ulcers, conjunctivitis, and blepharitis caused by susceptible bacterial strains.

Each ml eye drops contains:

• Active Substance: Ciprofloxacin Hydrochloride BP equivalent to Ciprofloxacin 3 mg
• Preservative: Benzalkonium Chloride 0.06 mg

Ciprofloxacin exhibits in vitro activity against a wide range of Gram-negative and Gram-positive organisms. It is bactericidal and acts by inhibiting the A subunits of DNA gyrase (topoisomerase), which is essential for bacterial DNA replication.

For Corneal Ulcers: Instill 2 drops into the affected eye every 15 minutes for the first six hours and then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill 2 drops into the affected eye hourly. On the third through the fourteenth day, place 2 drops into the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.

Bacterial Conjunctivitis/Blepharitis: Instill 1 drop to the conjunctival sac(s) every two hours for two days and 1 drop every four hours for the next five days.

Pediatric use: Safety and effectiveness in children under 1 year of age have not been established.

Specific drug interaction studies have not been conducted with ophthalmic Ciprofloxacin. However, systemic use of quinolones has shown increased plasma levels of theophylline, interference with caffeine metabolism, enhancement of warfarin effects, and transient increases in serum creatinine when used with cyclosporine.

Contraindicated in patients with a history of hypersensitivity to Ciprofloxacin or any component of the formulation. Hypersensitivity to other quinolones (e.g., nalidixic acid) may also contraindicate its use.

The most common adverse reaction is local burning or discomfort. In corneal ulcer cases, white crystalline deposits may occur. Other reactions include lid margin crusting, foreign body sensation, itching, conjunctival hyperemia, bad taste, corneal staining, keratopathy/keratitis, allergic reactions, eyelid edema, tearing, photophobia, corneal infiltrates, nausea, and decreased vision.

There are no adequate and well-controlled studies in pregnant women. Ciprofloxacin ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Prolonged use may lead to overgrowth of non-susceptible organisms including fungi. If superinfection occurs, discontinue use and initiate appropriate therapy. Treatment should be stopped at the first sign of hypersensitivity or skin rash.

A topical overdose may be flushed from the eye(s) with warm tap water.

Aural Anti-bacterial preparations, Ophthalmic antibacterial drugs

Store at room temperature, protect from light. The contents should not be used more than one month after first opening of the bottle.